tbuckley/cabot-search huggingface dataset:
VIEWING PULMONARY HYPERTENSION THROUGH A PEDIATRIC LENS
Authors: Stuti Agarwal, Jeffrey Fineman, David N. Cornfield, Cristina M. Alvira, Roham T. Zamanian, Kara Goss, Ke Yuan, Sebastien Bonnet, Olivier Boucherat, Soni Pullamsetti, Miguel A. Alcázar, Elena Goncharova, Tatiana V. Kudryashova, Mark R. Nicolls, Vinicio de Jesús Pérez
Journal: European Respiratory Journal (2024)
High risk of lung cancer in surfactant-related gene variant carriers
Authors: Alexandre Brudon, Marie Legendre, Arthur Mageau, Julien Bermudez, Philippe Bonniaud, Diane Bouvry, Jacques Cadranel, Aurélie Cazes, Bruno Crestani, Tristan Dégot, Céline Delestrain, Rémi Diesler, Ralph Epaud, Quentin Philippot, Nathalie Théou-Anton, Caroline Kannengiesser, Ibrahima Ba, Marie-Pierre Debray, Pascale Fanen, Efrosine Manali, Spyros Papiris, Nadia Nathan, Serge Amselem, Antoine Gondouin, Anne Guillaumot, Claire Andréjak, Stephane Jouneau, Guillaume Beltramo, Yurdagul Uzunhan, François Galodé, Virginie Westeel, Anas Mehdaoui, Sandrine Hirschi, Sylvie Leroy, Sylvain Marchand-Adam, Hilario Nunes, Clément Picard, Grégoire Prévot, Martine Reynaud-Gaubert, Paul De Vuyst, Lidwine Wemeau, Gautier Defossez, Gérard Zalcman, Vincent Cottin, Raphael Borie
Journal: European Respiratory Journal (2024)

Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.
Inflammatory and tissue injury marker dynamics in pediatric acute respiratory distress syndrome
Authors: Nadir Yehya, Thomas J. Booth, Gnana D. Ardhanari, Jill M. Thompson, L.K. Metthew Lam, Jacob E. Till, Mark V. Mai, Garrett Keim, Daniel J. McKeone, E. Scott Halstead, Patrick Lahni, Brian M. Varisco, Wanding Zhou, Erica L. Carpenter, Jason D. Christie, Nilam S. Mangalmurti
Journal: Journal of Clinical Investigation (2024)

BACKGROUND. The molecular signature of pediatric acute respiratory distress syndrome (ARDS) is poorly described, and the degree to which hyperinflammation or specific tissue injury contributes to outcomes is unknown. Therefore, we profiled inflammation and tissue injury dynamics over the first 7 days of ARDS, and associated specific biomarkers with mortality, persistent ARDS, and persistent multiple organ dysfunction syndrome (MODS).
Krüppel-like factor 10 protects against metabolic dysfunction-associated steatohepatitis by regulating HNF4α-mediated metabolic pathways
Authors: Xiaoli Pan, Shuwei Hu, Yanyong Xu, Raja Gopoju, Yingdong Zhu, Fathima N. Cassim Bawa, Hui Wang, Jiayou Wang, Zaid Batayneh, Alyssa Clark, Yuhao Zeng, Li Lin, Xinwen Wang, Liya Yin, Yanqiao Zhang
Journal: Metabolism (2024)

Krüppel-like factor 10 (KLF10), a zinc finger transcription factor, plays a pivotal role in modulating TGF-β-mediated cellular processes such as growth, apoptosis, and differentiation. Recent studies have implicated KLF10 in regulating lipid metabolism and glucose homeostasis. This study aimed to elucidate the precise role of hepatic KLF10 in developing metabolic dysfunction-associated steatohepatitis (MASH) in diet-induced obese mice.
Applications and Opportunities for Immune Cell CAR Engineering in Comparative Oncology
Authors: Antonia Rotolo, Matthew J. Atherton
Journal: Clinical Cancer Research (2024)

Abstract Chimeric antigen receptor (CAR) T–adoptive cell therapy has transformed the treatment of human hematologic malignancies. However, its application for the treatment of solid tumors remains challenging. An exciting avenue for advancing this field lies in the use of pet dogs, in which cancers that recapitulate the biology, immunological features, and clinical course of human malignancies arise spontaneously. Moreover, their large size, outbred genetic background, shared environment with humans, and immunocompetency make dogs ideal for investigating and optimizing CAR therapies before human trials. Here, we will outline how challenges in early clinical trials in patients with canine lymphoma, including issues related to autologous CAR T-cell manufacturing, limited CAR T-cell persistence, and tumor antigen escape, mirrored challenges observed in human CAR T trials. We will then highlight emerging adoptive cell therapy strategies currently under investigation in dogs with hematological and solid cancers, which will provide crucial safety and efficacy data on novel CAR T regimens that can be used to support clinical trials. By drawing from ongoing studies, we will illustrate how canine patients with spontaneous cancer may serve as compelling screening platforms to establish innovative CAR therapy approaches and identify predictive biomarkers of response, with a specific emphasis on solid tumors. With increased funding for canine immunotherapy studies, multi-institutional investigations are poised to generate highly impactful clinical data that should translate into more effective human trials, ultimately benefiting both human and canine cancer patients.
Immunotherapy in Gastric Cancer—Choosing Methods or Results
Authors: Thierry Alcindor
Journal: JAMA Oncology (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Statins Do Not Significantly Affect Oxidative Nitrosative Stress Biomarkers in the PREVENT Randomized Clinical Trial
Authors: Igor Makhlin, Biniyam G. Demissei, Ralph D'Agostino, W. Greg Hundley, Camelia Baleanu-Gogonea, Nicholas S. Wilcox, Anna Chen, Amanda M. Smith, Nathaniel Sean O'Connell, James L. Januzzi, Glenn J. Lesser, Marielle Scherrer-Crosbie, Borja Ibáñez, W.H. Wilson Tang, Bonnie Ky
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT; NCT01988571) randomized patients with breast cancer or lymphoma receiving anthracyclines to atorvastatin 40 mg daily or placebo. We evaluated the effects of atorvastatin on oxidative and nitrosative stress biomarkers, and explored whether these biomarkers could explain the lack of effect of atorvastatin on LVEF (left ventricular ejection fraction) in PREVENT. Patients and Methods: Blood samples were collected and cardiac MRI was performed before doxorubicin initiation and at 6 and 24 months. Thirteen biomarkers [arginine–nitric oxide metabolites, paraoxonase-1 (PON-1) activity, and myeloperoxidase] were measured. Dimensionality reduction using principal component analysis was used to define biomarker clusters. Linear mixed-effects models determined the changes in biomarkers over time according to treatment group. Mediation analysis determined whether biomarker clusters explained the lack of effect of atorvastatin on LVEF. Results: Among 202 participants with available biomarkers, median age was 53 years; 86.6% had breast cancer; median LVEF was 62%. Cluster 1 levels, reflecting arginine methylation metabolites, were lower over time with atorvastatin, although this was not statistically significant (P = 0.081); Cluster 2 levels, reflecting PON-1 activity, were significantly lower with atorvastatin (P = 0.024). There were no significant changes in other biomarker clusters (P &amp;gt; 0.05). Biomarker clusters did not mediate an effect of atorvastatin on LVEF (P &amp;gt; 0.05). Conclusions: Atorvastatin demonstrated very modest effects on oxidative/nitrosative stress biomarkers in this low cardiovascular risk population. Our findings provide potential mechanistic insight into the lack of effect of atorvastatin on LVEF in the PREVENT trial.
Diversity and Evolution of Frog Visual Opsins: Spectral Tuning and Adaptation to Distinct Light Environments
Authors: Ryan K Schott, Matthew K Fujita, Jeffrey W Streicher, David J Gower, Kate N Thomas, Ellis R Loew, Abraham G Bamba Kaya, Gabriela B Bittencourt-Silva, C Guillherme Becker, Diego Cisneros-Heredia, Simon Clulow, Mateo Davila, Thomas J Firneno, Célio F B Haddad, Sunita Janssenswillen, Jim Labisko, Simon T Maddock, Michael Mahony, Renato A Martins, Christopher J Michaels, Nicola J Mitchell, Daniel M Portik, Ivan Prates, Kim Roelants, Corey Roelke, Elie Tobi, Maya Woolfolk, Rayna C Bell
Journal: Molecular Biology and Evolution (2024)

Abstract Visual systems adapt to different light environments through several avenues including optical changes to the eye and neurological changes in how light signals are processed and interpreted. Spectral sensitivity can evolve via changes to visual pigments housed in the retinal photoreceptors through gene duplication and loss, differential and coexpression, and sequence evolution. Frogs provide an excellent, yet understudied, system for visual evolution research due to their diversity of ecologies (including biphasic aquatic-terrestrial life cycles) that we hypothesize imposed different selective pressures leading to adaptive evolution of the visual system, notably the opsins that encode the protein component of the visual pigments responsible for the first step in visual perception. Here, we analyze the diversity and evolution of visual opsin genes from 93 new eye transcriptomes plus published data for a combined dataset spanning 122 frog species and 34 families. We find that most species express the four visual opsins previously identified in frogs but show evidence for gene loss in two lineages. Further, we present evidence of positive selection in three opsins and shifts in selective pressures associated with differences in habitat and life history, but not activity pattern. We identify substantial novel variation in the visual opsins and, using microspectrophotometry, find highly variable spectral sensitivities, expanding known ranges for all frog visual pigments. Mutations at spectral-tuning sites only partially account for this variation, suggesting that frogs have used tuning pathways that are unique among vertebrates. These results support the hypothesis of adaptive evolution in photoreceptor physiology across the frog tree of life in response to varying environmental and ecological factors and further our growing understanding of vertebrate visual evolution.
Cell States in Cancer: Drivers, Passengers, and Trailers
Authors: Gaetano Gargiulo, Michela Serresi, Jean-Christophe Marine
Journal: Cancer Discovery (2024)

Summary: Cancer is traditionally perceived through a genetic lens, with therapeutic strategies targeting oncogenic driver mutations. We advocate an overarching framework recognizing tumors as comprising driver, passenger, and trailer cell states: Tailoring therapies to simultaneously target driver genetics and cell states may enhance effectiveness and durability.
Pushing the Boundaries of Liquid Biopsies for Early Precision Intervention
Authors: Valsamo Anagnostou, Victor E. Velculescu
Journal: Cancer Discovery (2024)

Summary: Liquid biopsies are emerging as powerful minimally invasive approaches that have the potential to solve several long-standing problems spanning the continuum of cancer care: early detection of cancer, minimal residual disease tracking, and refinement of the heterogeneity of clinical responses together with therapeutic response monitoring in the metastatic setting. Existing challenges driven by technical limitations and establishment of the clinical value of liquid biopsies represent fields of active research that call for convergence science approaches to bridge scientific discovery with clinical care.
Precision Endpoints for Contemporary Precision Oncology Trials
Authors: Regina Hoo, Kevin L.M. Chua, Pankaj Kumar Panda, Anders J. Skanderup, Daniel S.W. Tan
Journal: Cancer Discovery (2024)

Summary: Traditional endpoints such as progression-free survival and overall survival do not fully capture the pharmacologic and pharmacodynamic effects of a therapeutic intervention. Incorporating mechanism-driven biomarkers and validated surrogate proximal endpoints can provide orthogonal readouts of anti-tumor activity and delineate the relative contribution of treatment components on an individual level, highlighting the limitation of solely relying on aggregated readouts from clinical trials to facilitate go/no-go decisions for precision therapies.
“A Mighty Flame Can Follow a Tiny Spark”: Is This the Case of C-Jun N-Terminal Kinase 1 (JNK) Inhibitors in Idiopathic Pulmonary Fibrosis?
Authors: Fabrizio Luppi, Giovanni Ferrara
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

""A Mighty Flame Can Follow a Tiny Spark": Is This the Case of C-Jun N-Terminal Kinase 1 (JNK) Inhibitors in Idiopathic Pulmonary Fibrosis? ." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Platelet-derived TGF-β1 induces functional reprogramming of myeloid-derived suppressor cells in immune thrombocytopenia
Authors: Lingjun Wang, Haoyi Wang, Mingfang Zhu, Xiaofei Ni, Lu Sun, Wanru Wang, Jie Xie, Yubin Li, Yitong Xu, Ruting Wang, Shouqing Han, Ping Zhang, Jun Peng, Ming Hou, Yu Hou
Journal: Blood (2024)
Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial
Authors: Sumanta K. Pal, Petros Grivas, Shilpa Gupta, Nazli Dizman, Zeynep Zengin, Begona P. Valderrama, Alejo Rodriguez-Vida, Florian Roghmann, Elena Sevillano Fernandez, Surena F. Matin, Yohann Loriot, Srikala S. Sridhar, Guru Sonpavde, Mark T. Fleming, Seth P. Lerner, Joaquim Bellmunt, Viraj Master, Abhishek Tripathi, Kim Davis, David van Veenhuyzen, Richard Weng, Siamak Daneshmand
Journal: European Urology (2024)
Synergistic Antimicrobial Glycyrrhizic Acid‐Based Functional Biosensing Composite for Sensitive Glucose Monitoring and Collaborative Wound Healing
Authors: Xiao Wang, Haoling Huo, Yanming Zhong, Yingfei Yang, Huaijun Lin, Lin Cao, Qiwei Wang, Congjie Xu, Zhidan Lin, Wei Li, Peng Zhang
Journal: Advanced Healthcare Materials (2024)

High glucose blood and bacterial infection remain major issues for the slow healing of diabetic wounds, so developing functional biosensing composite with excellent antibacterial and remarkable glucose response sensitivity is necessary and prospective. Herein, by in situ synthesis AgNPs on the surface of self-prepared PTIGA elastomers, PTIGA-AgNPs conductive composites are obtained with efficient synergistic antibacterial effect, excellent mechanical and self-healing properties. The strain of the composites can reach 1800%, and its self-healing efficiency exceeds 90% at 60 °C within 8 h. Both elastomers and composites represent excellent biocompatibility and the antibacterial rate against E. coli and S. aureus exceeded 90%. Moreover, the biosensor assembled from the conductive composites exhibits excellent glucose response sensitivity and stability, with a sensitivity coefficient of 0.518 mA mm
Closing the gender authorship gap
Authors: Manon C. W. Spaander
Journal: Endoscopy (2024)

Since the mid-1960s, slightly more men than women have been present on this planet. In 2022, 4 billion males and 3.95 billion females were living worldwide, implying 50.4% of the world population is male and 49.6% female. By 2050, however, it is expected that the sex ratio will even out and, after 2050, females will outnumber males [1]. Currently, women already outnumber men in the older age groups because of the differences in mortality between men and women, with woman tending to live longer than men.
Circulating extracellular vesicles as biomarker for diagnosis, prognosis, and monitoring in glioblastoma patients
Authors: Franz L Ricklefs, Kathrin Wollmann, Amanda Salviano-Silva, Richard Drexler, Cecile L Maire, Michael G Kaul, Rudolph Reimer, Ulrich Schüller, Sarina Heinemann, Katharina Kolbe, Tobias Mummert, Markus Glatzel, Sven Peine, Jens Gempt, Manfred Westphal, Lasse Dührsen, Katrin Lamszus
Journal: Neuro-Oncology (2024)

Abstract Background Extracellular vesicles (EVs) obtained by noninvasive liquid biopsy from patient blood can serve as biomarkers. Here, we investigated the potential of circulating plasma EVs to serve as an indicator in the diagnosis, prognosis, and treatment response of glioblastoma patients. Methods Plasma samples were collected from glioblastoma patients at multiple timepoints before and after surgery. EV concentrations were measured by nanoparticle tracking analysis and imaging flow cytometry. Tumor burden and edema were quantified by 3D reconstruction. EVs and tumors were further monitored in glioma-bearing mice. Results Glioblastoma patients displayed a 5.5-fold increase in circulating EVs compared to healthy donors (P &amp;lt; .0001). Patients with higher EV levels had significantly shorter overall survival and progression-free survival than patients with lower levels, and the plasma EV concentration was an independent prognostic parameter for overall survival. EV levels correlated with the extent of peritumoral fluid-attenuated inversion recovery hyperintensity but not with the size of the contrast-enhancing tumor, and similar findings were obtained in mice. Postoperatively, EV concentrations decreased rapidly back to normal levels, and the magnitude of the decline was associated with the extent of tumor resection. EV levels remained low during stable disease, but increased again upon tumor recurrence. In some patients, EV resurgence preceded the magnetic resonance imaging detectability of tumor relapse. Conclusions Our findings suggest that leakiness of the blood-brain barrier may primarily be responsible for the high circulating EV concentrations in glioblastoma patients. Elevated EVs reflect tumor presence, and their quantification may thus be valuable in assessing disease activity.
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Authors: Qingyang Shi, Yang Wang, Qiukui Hao, Per Olav Vandvik, Gordon Guyatt, Jing Li, Zhe Chen, Shishi Xu, Yanjiao Shen, Long Ge, Feng Sun, Ling Li, Jiajie Yu, Kailei Nong, Xinyu Zou, Siyi Zhu, Cong Wang, Shengzhao Zhang, Zhi Qiao, Zhongyu Jian, Ya Li, Xinyi Zhang, Kerun Chen, Furong Qu, Yuan Wu, Yazhou He, Haoming Tian, Sheyu Li
Journal: The Lancet (2024)
Point-of-care C-reactive protein and Xpert MTB/RIF Ultra for tuberculosis screening and diagnosis in unselected antiretroviral therapy initiators: a prospective, cross-sectional, diagnostic accuracy study
Authors: Byron W P Reeve, Gcobisa Ndlangalavu, Hridesh Mishra, Zaida Palmer, Happy Tshivhula, Loren Rockman, Selisha Naidoo, Desiree L Mbu, Charissa C Naidoo, Brigitta Derendinger, Gerhard Walzl, Stephanus T Malherbe, Paul D van Helden, Fred C Semitala, Christina Yoon, Rishi K Gupta, Mahdad Noursadeghi, Robin M Warren, Grant Theron
Journal: The Lancet Global Health (2024)

Tuberculosis, a major cause of death in people living with HIV, remains challenging to diagnose. Diagnostic accuracy data are scarce for promising triage and confirmatory tests such as C-reactive protein (CRP), sputum and urine Xpert MTB/RIF Ultra (Xpert Ultra), and urine Determine TB LAM Ag (a lateral flow lipoarabinomannan [LF-LAM] test), without symptom selection. We evaluated novel triage and confirmatory tests in ambulatory people with HIV initiating antiretroviral therapy (ART).
Phage resistance in Klebsiella pneumoniae and bidirectional effects impacting antibiotic susceptibility
Authors: Sue C. Nang, Jing Lu, Heidi H. Yu, Hasini Wickremasinghe, Mohammad A.K. Azad, Meiling Han, Jinxin Zhao, Gauri Rao, Phillip J. Bergen, Tony Velkov, Norelle Sherry, David T. McCarthy, Saima Aslam, Robert T. Schooley, Benjamin P. Howden, Jeremy J. Barr, Yan Zhu, Jian Li
Journal: Clinical Microbiology and Infection (2024)
Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy
Authors: Léa Guerassimoff, Marianne Ferrere, Simon Van Herck, Samy Dehissi, Valérie Nicolas, Bruno G. De Geest, Julien Nicolas
Journal: Journal of Controlled Release (2024)

Despite their great versatility and ease of functionalization, most polymer-based nanocarriers intended for use in drug delivery often face serious limitations that can prevent their clinical translation, such as uncontrolled drug release and off-target toxicity, which mainly originate from the burst release phenomenon. In addition, residual solvents from the formulation process can induce toxicity, alter the physico-chemical and biological properties and can strongly impair further pharmaceutical development. To address these issues, we report polymer prodrug nanoparticles, which are prepared without organic solvents via an all-aqueous formulation process, and provide sustained drug release. This was achieved by the "drug-initiated" synthesis of well-defined copolymer prodrugs exhibiting a lower critical solution temperature (LCST) and based on the anticancer drug gemcitabine (Gem). After screening for different structural parameters, prodrugs based on amphiphilic diblock copolymers were formulated into stable nanoparticles by all-aqueous nanoprecipitation, with rather narrow particle size distribution and average diameters in the 50-80 nm range. They exhibited sustained Gem release in human serum and acetate buffer, rapid cellular uptake and significant cytotoxicity on A549 and Mia PaCa-2 cancer cells. We also demonstrated the versatility of this approach by formulating Gem-based polymer prodrug nanoparticles loaded with doxorubicin (Dox) for combination therapy. The dual-drug nanoparticles exhibited sustained release of Gem in human serum and acidic release of Dox under accelerated pathophysiological conditions. Importantly, they also induced a synergistic effect on triple-negative breast cancer line MDA-MB-231, which is a relevant cell line to this combination.
A Rare Case of Abnormal Diffuse Brain Uptake on an 123I MIBG Scan in a Patient With High-Risk Neuroblastoma
Authors: Deepashri Basavalingu, Murat Sadic, Safia Cheeney, Marguerite T. Parisi
Journal: Clinical Nuclear Medicine (2024)

123I-meta-iodobenzylguanidine (123I-MIBG) is extensively used for initial staging and response evaluation in children with neuroblastoma. Physiological uptake of 123I-MIBG occurs in the salivary glands, liver, adrenal gland, myocardium, bowel, and thyroid gland. 123I-MIBG cannot cross an intact blood-brain barrier. We present the rare case of a 3-year-old boy with neuroblastoma and meningeal metastases who underwent an 123I-MIBG scan for disease restaging that showed abnormal brain uptake. Abnormal MIBG uptake in the brain can occur if there is disruption of the blood-brain barrier either secondary to metastases or after damage to blood-brain barrier.